|
 |
商品名 |
|
|
商品名仅供参考, 药品所用的辅料可能依国家或厂商不同有所不同。
|
|
Acetaflur |
墨西哥 |
|
Asoleudox |
墨西哥 |
|
Beneflur |
墨西哥, 西班牙 |
|
Fludabin |
秘鲁 |
|
Fludacel |
印度, 秘鲁 |
|
Fludakebir |
秘鲁 |
|
Fludalym |
土耳其 |
|
Fludara |
丹麦, 伊朗, 匈牙利, 卢森堡, 印度, 哥伦比亚, 埃及, 奥地利, 委内瑞拉, 德国, 意大利, 新西蘭, 智利, 比利时, 沙特阿拉伯, 法国, 波兰, 爱尔兰, 瑞典, 瑞士, 罗马尼亚, 美国, 芬兰, 英国, 荷兰, 葡萄牙, 马来西亚 |
|
Fludarabin |
冰岛, 意大利, 挪威, 瑞典, 瑞士 |
|
Fludarabina |
哥伦比亚, 秘鲁, 罗马尼亚, 西班牙, 阿根廷 |
|
Fludarabine |
伊朗, 加拿大, 挪威, 新西蘭, 比利时, 瑞士, 美国 |
|
Fludarin |
印度 |
|
Fludarosa |
阿根廷 |
|
Forclina |
秘鲁 |
|
Ludabina |
哥伦比亚, 智利 |
|
Mepredin |
秘鲁 |
|
Naprobin |
印度 |
|
Neoflubin |
伊朗 |
|
|
 |
 |
引用文献 : Fludarabine phosphate |
|
|
种类 |
出版物 |
| 3 |
文献 |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 81 |
文献 |
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678. |
| 84 |
文献 |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 99 |
文献 |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 169 |
文献 |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 182 |
文献 |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
文献 |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 249 |
文献 |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 307 |
文献 |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 492 |
文献 |
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 905 |
文献 |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 1410 |
文献 |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1423 |
文献 |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 3306 |
文献 |
Trittler R.
New stability studies for fludarabine according to the European Pharmacopoeia 7.0
EJOP 2012 ; 6, 1: 1-2. |
| 3595 |
实验室 |
Aciclovir - Summary of Product Characteristics
Hospira 2009 |
| 3604 |
实验室 |
Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2012 |
| 3637 |
实验室 |
Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
Hameln Pharmaceuticals 2014 |
| 3644 |
实验室 |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3670 |
文献 |
Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30. |
| 3838 |
实验室 |
Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007 |
| 4398 |
文献 |
Smith E. K., Shergold J.A., McWhinney B.C.
Compatibility of intravenous busulfan with BBraun giving sets, fludarabine and Posiflush.
J Pharm Pract and Res 2020 |
| 4964 |
实验室 |
GLUCONATE DE CALCIUM 10 % B.BRAUN, solution pour perfusion - Résumé des caractéristiques du produit.
B BRAUN MELSUNGEN AG 2019 |
|
|
